share_log

BTIG Initiates Coverage On Kymera Therapeutics With Buy Rating, Announces Price Target of $60

BTIG Initiates Coverage On Kymera Therapeutics With Buy Rating, Announces Price Target of $60

BTIG對Kymera Therapeutics啓動覆蓋,評級爲買入,目標價格爲60美元。
Benzinga ·  2024/12/11 01:56  · 評級/大行評級

BTIG analyst Jeet Mukherjee initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Buy rating and announces Price Target of $60.

BTIG 分析師Jeet Mukherjee開始對Kymera Therapeutics(納斯達克:KYMR)進行覆蓋,給出買入評級,並宣佈目標價爲60美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論